Goodman Group (ASX:GMG) has announced a $4bn equity capital raise to accelerate its expansion in data centre operations. The company plans to issue 119.4 million new shares at a set price of $33.50 each, with up to $400m allocated for existing shareholders through a share purchase plan. The move is aimed at capitalising on surging demand for data infrastructure. Shares are in a trading halt, last trading at $35.98.
Stockland’s (ASX:SGP) net profit after tax has more than doubled to $245m for the six months to December, up from $102m a year earlier. The increase was largely driven by an upwards revaluation of its investment properties, reflecting a stronger property market. Shares are trading 4.28% lower at $5.14.
Cleanaway Waste Management (ASX:CWY), Australia’s largest waste management company, has raised its interim dividend after posting a 12.2% rise in earnings before interest and tax to $195.2m for the first half. The company credited cost efficiencies and higher volumes for the earnings uplift. Shares are trading 1.3% lower at $2.67.
Reach Resources (ASX:RR1) has reported assay results from the first two of 14 RC drill holes at its 100%-owned Murchison South gold project in Western Australia. The results support the interim mineralisation model, with high-grade gold found in quartz veins within hornblende gneiss. CEO Jeremy Bower said the findings validate historic drilling at the Blue Heaven deposit, with assays from the remaining 12 holes pending. Shares are trading 7.14% lower at 1.3 cents.
OD6 Metals (ASX:OD6) has reported results from surface soil sampling and a Fixed Loop Electromagnetics (FLEM) geophysics survey at its Gulf Creek Copper Project in northern NSW. The surveys have identified multiple high-priority drill targets, with anomalous copper extending over several kilometres, indicating potential for a large-scale VMS system. Shares are trading 2.17% lower at 4.5 cents.
Optiscan Imaging (ASX:OIL) has annouced InForm™, a microscopic medical imaging device designed to enhance pathology workflows with real-time digital insights. Expanding Optiscan’s portfolio into the pathology market, InForm™ supports laboratory, point-of-care, and digital pathology settings, enabling faster and more accurate diagnoses. Developed in Melbourne with Design + Industry, the device aims to improve efficiency and advance precision medicine. Shares are trading 3.23% higher at 16 cents.
